Back to News
Market Impact: 0.35
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Source: benzinga.com
Corporate EarningsM&A & RestructuringHealthcare & BiotechCompany Fundamentals
Novartis reported mixed third-quarter earnings, including an estimated $1.9 billion impairment charge tied to its $12 billion Avidity Biosciences deal. The charge was primarily driven by a shifted timeline as additional clinical work remains to be completed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
NVS-0.50
More News
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- ‘Why do we value a Mars bar more than life-saving medicine?’ Sandoz CEO calls for level playing field with cheap Chinese antibiotics
- Who controls powerful AI? Anthropic has a plan for long after its leaders depart
- European shares fall as HSBC slump and energy fears offset AI glow
- Who’s really in charge at Anthropic after the IPO?
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost